Answers are grounded in this paper and cite their sources.
In silico case study identifies EMB-3 as a potential anti-fibrotic candidate for skin scar regeneration, suggesting effective treatment options.
Correction (new version, 2026-07-18) — integrity correction. Corrected version (2026-07-18). This preprint contains no fabricated panel of its own; it had referenced a companion 15-compound MMP-1 calibration (in preprint #8) that has since been withdrawn because its panel carried fabricated potencies. Those two references are updated to state that the Boltz-2 affinity_probability_binary metric is used purely as a relative-ranking signal (consistent with the model's reported held-out Spearman of about 0.55–0.65); no other content changes. In silico only. HanCheongWoo ¹,²,³ ORCID: [0009-0004-4805-8815](https://orcid.org/0009-0004-4805-8815)
No takes yet. Share an insight, caveat, or question.
Cheongwoo Han (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: